RTSN Stock Chart & Stats
11.32
0.79(7.50%)
―
--
Day’s Range― - ―
52-Week Range9.66 - 11.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$89.22M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,881,599
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Retension Pharmaceuticals Inc News
RTSN FAQ
What was Retension Pharmaceuticals Inc’s price range in the past 12 months?
Retension Pharmaceuticals Inc lowest stock price was 9.66 and its highest was 11.79 in the past 12 months.
What is Retension Pharmaceuticals Inc’s market cap?
Retension Pharmaceuticals Inc’s market cap is $89.22M.
When is Retension Pharmaceuticals Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Retension Pharmaceuticals Inc’s earnings last quarter?
Currently, no data Available
Is Retension Pharmaceuticals Inc overvalued?
According to Wall Street analysts Retension Pharmaceuticals Inc’s price is currently Undervalued.
Does Retension Pharmaceuticals Inc pay dividends?
Retension Pharmaceuticals Inc does not currently pay dividends.
What is Retension Pharmaceuticals Inc’s EPS estimate?
Retension Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Retension Pharmaceuticals Inc have?
Retension Pharmaceuticals Inc has 7,881,599 shares outstanding.
What happened to Retension Pharmaceuticals Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Retension Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in RTSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Retension Pharmaceuticals Inc
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.